Neoplasm Treatment - APAC
APAC- In APAC, the Neoplasm Treatment market is anticipated to witness a significant growth in revenue, with a projected value of US$100.40bn by the year 2024.
- Furthermore, it is expected to exhibit a steady annual growth rate (CAGR 2024-2028) of 5.31%, leading to a market volume of US$123.50bn by 2028.
- When compared globally, United States is projected to generate the highest revenue in the Neoplasm Treatment market, with an estimated value of US$90.56bn by 2024.
- APAC's neoplasm treatment market is rapidly advancing, with Japan leading the way in innovative therapies and research.
Definition:
Neoplasm Treatment refers to the medical and surgical treatments of cancer patients who require hospitalization for their care. This includes surgeries, chemotherapy, radiation therapy, immunotherapy, and/or other treatments that require close monitoring and support from healthcare professionals. Patients will typically stay in a hospital for several days to several weeks, depending on the severity of their condition. This allows hospitals to provide the highest level of medical support and to help manage symptoms and/or side effects of the patients while they receive treatment.
Additional information:
The Neoplasm Treatments market comprises revenues and average revenue per capita. Market values represent revenues paid to hospitals by the respective healthcare payers (including VAT, if applicable). Reported market revenues include spending by consumers (B2C), enterprises (B2B), and governments (B2G). Revenues are allocated to the country where the money is spent.
In-Scope
- Inpatient treatment of cancer patients
Out-Of-Scope
- Long-term rehabilitative care
- Home-based rehabilitative care
